Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Blood pressure variability and cardiovascular risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).

Poortvliet RK, Ford I, Lloyd SM, Sattar N, Mooijaart SP, de Craen AJ, Westendorp RG, Jukema JW, Packard CJ, Gussekloo J, de Ruijter W, Stott DJ.

PLoS One. 2012;7(12):e52438. doi: 10.1371/journal.pone.0052438. Epub 2012 Dec 20.

2.

Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).

Lloyd SM, Stott DJ, de Craen AJ, Kearney PM, Sattar N, Perry I, Packard CJ, Briggs A, Marchbank L, Comber H, Jukema JW, Westendorp RG, Trompet S, Buckley BM, Ford I.

PLoS One. 2013 Sep 2;8(9):e72642. doi: 10.1371/journal.pone.0072642. eCollection 2013.

3.

Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).

Freeman DJ, Robertson M, Brown EA, Rumley A, Tobias ES, Frölich M, Slagboom PE, Jukema JW, de Craen AJ, Sattar N, Ford I, Gaw A, Greer IA, Lowe GD, Stott DJ.

BMC Geriatr. 2011 Feb 22;11:8. doi: 10.1186/1471-2318-11-8.

4.

Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population.

Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, Jaaskivi M, Nachev C, Parati G, O'Brien ET, Tuomilehto J, Webster J, Bulpitt CJ, Fagard RH; Syst-Eur investigators.

J Hypertens. 2003 Dec;21(12):2251-7.

PMID:
14654744
5.

Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis.

Ford I, Bezlyak V, Stott DJ, Sattar N, Packard CJ, Perry I, Buckley BM, Jukema JW, de Craen AJ, Westendorp RG, Shepherd J.

PLoS Med. 2009 Jan 20;6(1):e16. doi: 10.1371/journal.pmed.1000016.

6.

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.

Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators.

Circulation. 2004 Nov 2;110(18):2809-16. Epub 2004 Oct 18.

7.

C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).

Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Shepherd J; PROSPER Study Group.

Circulation. 2007 Feb 27;115(8):981-9. Epub 2007 Feb 5.

8.

Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).

Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER Study Group.

Circulation. 2005 Nov 15;112(20):3058-65. Epub 2005 Nov 7.

9.

Association of visit-to-visit variability in blood pressure with cognitive function in old age: prospective cohort study.

Sabayan B, Wijsman LW, Foster-Dingley JC, Stott DJ, Ford I, Buckley BM, Sattar N, Jukema JW, van Osch MJ, van der Grond J, van Buchem MA, Westendorp RG, de Craen AJ, Mooijaart SP.

BMJ. 2013 Jul 29;347:f4600. doi: 10.1136/bmj.f4600.

10.

Biological correlates of blood pressure variability in elderly at high risk of cardiovascular disease.

Poortvliet RK, Lloyd SM, Ford I, Sattar N, de Craen AJ, Wijsman LW, Mooijaart SP, Westendorp RG, Jukema JW, de Ruijter W, Gussekloo J, Stott DJ.

Am J Hypertens. 2015 Apr;28(4):469-79. doi: 10.1093/ajh/hpu181. Epub 2014 Oct 8.

PMID:
25298176
11.

Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk.

Drewes YM, Poortvliet RK, Blom JW, de Ruijter W, Westendorp RG, Stott DJ, Blom HJ, Ford I, Sattar N, Wouter Jukema J, Assendelft WJ, de Craen AJ, Gussekloo J.

J Am Geriatr Soc. 2014 Feb;62(2):213-21. doi: 10.1111/jgs.12660. Epub 2014 Jan 21.

12.

Systolic blood pressure variability is an important predictor of cardiovascular outcomes in elderly hypertensive patients.

Chowdhury EK, Owen A, Krum H, Wing LM, Nelson MR, Reid CM; Second Australian National Blood Pressure Study Management Committee.

J Hypertens. 2014 Mar;32(3):525-33. doi: 10.1097/HJH.0000000000000028.

PMID:
24481213
13.

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

JAMA. 2002 Dec 18;288(23):2998-3007.

PMID:
12479764
14.

Effect of pravastatin on blood pressure in people with cardiovascular disease.

Tonelli M, Sacks F, Pfeffer M, Lopez-Jimenez F, Jhangri GS, Curhan G.

J Hum Hypertens. 2006 Aug;20(8):560-5. Epub 2006 Apr 20.

PMID:
16625234
15.

Visit-to-visit systolic blood pressure variability predicts all-cause and cardiovascular mortality after lacunar infarct.

Lau KK, Wong YK, Chang RS, Teo KC, Hon SF, Chan KH, Wat KL, Cheung RT, Li LS, Siu CW, Ho SL, Tse HF.

Eur J Neurol. 2014 Feb;21(2):319-25. doi: 10.1111/ene.12310. Epub 2013 Nov 23.

PMID:
24267182
16.

Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5·5-year prospective analysis.

Hsieh YT, Tu ST, Cho TJ, Chang SJ, Chen JF, Hsieh MC.

Eur J Clin Invest. 2012 Mar;42(3):245-53. doi: 10.1111/j.1365-2362.2011.02574.x. Epub 2011 Aug 5.

PMID:
21815887
17.

Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study.

Stewart RA, North FM, Sharples KJ, Simes RJ, Tonkin AM, White HD; Long-term Intervention with Pravastatin in Ischaemic Disease Study Investigators.

N Z Med J. 2008 Feb 15;121(1269):11-23.

PMID:
18278078
18.

Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.

McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D.

Am J Kidney Dis. 2014 Nov;64(5):714-22. doi: 10.1053/j.ajkd.2014.06.008. Epub 2014 Jul 24.

PMID:
25064674
19.

Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease.

Tozawa M, Iseki K, Yoshi S, Fukiyama K.

Nephrol Dial Transplant. 1999 Aug;14(8):1976-81.

20.

KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.

Akao H, Polisecki E, Kajinami K, Trompet S, Robertson M, Ford I, Jukema JW, de Craen AJ, Westendorp RG, Shepherd J, Packard C, Buckley BM, Schaefer EJ.

Atherosclerosis. 2012 Feb;220(2):456-62. doi: 10.1016/j.atherosclerosis.2011.11.037. Epub 2011 Dec 7.

PMID:
22192511
Items per page

Supplemental Content

Write to the Help Desk